Eric Burton, M.D.


M.D., University of Michigan School of Medicine
Residency, Neurology, University of Chicago
Board Certified, American Board of Psychiatry and Neurology
Fellowship, Neuro-oncology, University of California at San Francisco
Board Certified, UCNS Neuro-oncology

Curriculum Vitae

Current Positions:

Assistant Professor of Neurology and Neuro-oncology , Department of Neurology and the James Graham Brown Cancer Center

Clinical Focus and Research:

My clinical focus is on multi-disciplinary approaches to the treatment of Brain and Spinal cord cancers.  I work with surgical and radiation oncologists to ensure that my patients receive the most effective combination of treatment modalities and have access to the most innovative drugs for the treatment of cancer.

My research interests include the conduct of phase I and II clinical trials of new CNS therapeutics.

Literature Cited:

  1. Burton, E. Ugiliweneza,B. Woo,S. Skirboll, S. Boakye, M. “ A SEER-medicare data analysis of elderly glioblastoma patients: treatment patterns, outcomes and cost, Submitted for publication.
  2. Prados, M. Lamborn, K. Chang, S. Burton, E. Butowski, N. Malec, M. Kapedia, A. Rabbitt, J. Page, M. Federoff, A. “Phase I study of erlotinib HCL alone and in combination with temozolomide in patients with stable or recurrent malignant glioma.” Neuro-oncology 8(1):67-78 (2006)
  3. Burton, E. and Prados, M. “Management of primary malignant brain tumors in adults.” In: Brain Cancer Prados, M. (ed) B.C. Decker Inc., Hamilton,Ontario,Canada, 2001
  4. Phase I-II study of hypofractionated radiotherapy with concurrent Temozolomide followed by adjuvant Temolzolomide in patients over 70 years with newly diagnosed Glioblastoma.”   Principal Investigator: E. Burton. Identifier NCT01985087

PubMed Information